Analysts Turned Bearish on These 10 Stocks on Wednesday

Page 3 of 3

4. Alnylam (NASDAQ:ALNY)

Average Upside Potential: 86%

JPMorgan analyst Jessica Fye cut her price target on Alnylam to $254 from $369 on November 18 and kept an Overweight rating. After reviewing the company’s model, she lowered her Amvuttra revenue forecasts for every year from 2026 through 2030.

Alnylam is a biopharmaceutical company and a pioneer of RNA interference therapies. Its main drug, Amvuttra, is sold for ATTR-CM, a heart condition. In the third quarter of 2026, reported on October 29, global net product revenues reached $1.29 billion, and Amvuttra revenue grew 65% from a year earlier.

The company also kept its 2026 outlook, with revenue from its transthyretin (TTR) products expected between $4.20 billion and $4.50 billion. Fye’s lower forecasts run against the growth path for the drug that supplies most of those sales. Her target is a December 2027 price objective. The release also said Alnylam expanded enrollment in its TRITON-CM Phase 3 study of nucresiran, designed to support an expected ATTR-CM launch, and plans to start a pivotal study of brezosiran in Huntington’s disease. Readers following the group can find more names in our list of biotech stocks that billionaires own.

3. Strategy (NASDAQ:MSTR)

Average Upside Potential: 143%

Monness Crespi & Hardt cut Strategy to Sell from Neutral on November 18 and set a price target of $65. The firm cited weak Bitcoin prices and the company’s leverage and dilution, which it said could erode the premium investors pay for its Bitcoin holdings.

Strategy is built around the Bitcoin it holds on its balance sheet, and its results swing with that asset. The company reported its third-quarter 2026 results on October 29. Operating income in the period was $20.91 billion, almost entirely a $20.91 billion gain on digital assets, so the line says more about Bitcoin’s price than about an operating business. Bitcoin’s price therefore drives both the gain and the worry. Net income was $19.53 billion, or $44.75 per diluted share. Preferred dividends took $419.6 million out of that before earnings reached common shareholders.

Those preferred payments belong to the leverage question the call raises. Monness Crespi & Hardt had rated the stock Neutral before the call, so the move takes it from the middle of the rating scale to the bottom. We took up that tension in our piece on whether the leverage is still worth the complexity.

2. Summit Therapeutics (NASDAQ:SMMT)

Average Upside Potential: 178%

Bernstein analyst Jeffrey Walch cut Summit Therapeutics to Underperform from Market Perform on November 18 and lowered his price target to $8.30 from $11.90. He listed three mistakes in the company’s dealings with the FDA over its lung cancer drug and reduced the probability of success for every ongoing Phase 3 trial by 25%.

Summit develops ivonescimab, a cancer therapy. On November 15, the company said the FDA had issued a Complete Response Letter on its application to treat EGFR-mutated non-small cell lung cancer after prior therapy. The agency said substantial evidence of effectiveness was not established without a statistically significant overall survival benefit, and that a progression-free survival benefit alone did not support a positive benefit-risk profile.

Walch’s three criticisms concern the HARMONi trial: that Summit did not follow ICH E17 guidance, with 93% of progression-free survival events in patients from China; that it cut the data too early on four occasions; and that it could have been more open about regional risk. Summit pointed to five positive Phase III studies and to ongoing trials, including HARMONi-3 and HARMONi-7. Our story on the HARMONi-2 overall-survival result Akeso reported against pembrolizumab covers the survival question.

1. Cue Biopharma (NASDAQ:CUE)

Average Upside Potential: 1342%

B.Riley cut its price target on Cue Biopharma to $25 from $83 on November 18 and kept a Buy rating. The firm said the multi-year financing path is the largest driver of the cut.

Cue Biopharma is a clinical-stage drug developer focused on immune disorders, led by its anti-IgE candidate CUE-221. In the third quarter of 2026, reported on November 16, the company posted a net loss of $50.0 million, a sharp increase from the same period a year earlier. Cash and cash equivalents were $57.9 million at September 30, 2026, a figure that frames the financing question B.Riley raised.

The clinical data are the other side of the call. In patients with high baseline IgE who received 4 mg/kg of CUE-221 in the Phase 2 chronic spontaneous urticaria study, 78% reached complete hive resolution at week 12, against 0% on placebo. At week 28, 12 weeks after the last dose, the benefit persisted in the 4 mg/kg group. The company has also begun first-in-human dosing of CUE-401 in a Phase 1 trial. Our earlier look at whether longer relief could set Cue’s hives drug apartcovers the Phase 2 results.

READ NEXT: Nvidia Is Becoming More Than a Chipmaker. Can it Sustain Its Exceptional Margins? and Vertiv vs. Eaton: Which AI Power Stock Offers More Cash Flow for the Price?

Follow Insider Monkey on Google News.

Page 3 of 3